Depletion of CD4+ cells indeed abrogates the therapeutic efficacy (Supplementary Fig. 5A–D), demonstrating ZD55-IL-24 can activate the tumor-infiltrating CD4+ T cells, which help tumor rejection. This evidence concerns the gene CD4 and neoplasm.